# A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

> **NCT01201265** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01201265
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201265, "A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01201265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*